# Lupenone preserves T cell activity by recovery of CD40L expression and protection from cytotoxicity due to methamphetamine exposure

**Authors:** Hyun-Su Lee, Eun-Nam Kim, Gil-Saeng Jeong

PMC · DOI: 10.1371/journal.pone.0314054 · PLOS One · 2025-03-20

## TL;DR

Lupenone helps protect T cells from methamphetamine damage by boosting CD40L expression and reducing toxicity.

## Contribution

This study is the first to show lupenone's protective effects on T cell activity in methamphetamine-exposed cells.

## Key findings

- Lupenone pre-treatment reduces METH-induced toxicity in Jurkat T cells.
- Lupenone restores CD40L, IL-2, and CD69 expression in METH-exposed T cells.
- Lupenone protects T cells by modulating MAPK and PI3K/Akt/mTOR pathways.

## Abstract

Methamphetamine (METH) is one of the most highly compulsive drugs in the world and has become a major public health problem over the last two decades. Exposure to METH has been investigated to cause neuronal toxicity but little is known about the effect of METH on the activity and toxicity of T lymphocytes. Lupenone has been reported to possess anti-diabetic, anti-inflammatory and anti-apoptotic effects but little is known about whether lupenone has a protective effect on T cell activation in METH-exposed cells. We evaluated the cytotoxicity and cytoprotective effects of lupenone in METH-stimulated Jurkat T cells. Results from the inhibitor assay using CD40L blocking antibodies revealed that this was due to enhanced CD40L expression on the T cells by pre-treatment with lupenone. Pre-treatment with lupenone significantly reduces METH-induced toxicity by restoring the expression of anti-apoptotic proteins in activated T cells. The protective effects of lupenone on activated T cells exposed to METH were associated with the prevention of MAPK and PI3K/Akt/mTOR pathways. These data suggest lupenone protected T cell activity by elevating CD40L expression and cell viability in cells exposed to methamphetamine. Our data showed that lupenone treatment recovered the expression of IL-2 and CD69 in METH-exposed cells.

## Linked entities

- **Genes:** CD40LG (CD40 ligand) [NCBI Gene 959], IL2 (interleukin 2) [NCBI Gene 3558], CD69 (CD69 molecule) [NCBI Gene 969]
- **Chemicals:** methamphetamine (PubChem CID 1206), lupenone (PubChem CID 92158)

## Full-text entities

- **Genes:** MTOR (mechanistic target of rapamycin kinase) [NCBI Gene 2475] {aka FRAP, FRAP1, FRAP2, RAFT1, RAPT1, SKS}, CD40LG (CD40 ligand) [NCBI Gene 959] {aka CD154, CD40L, HIGM1, IGM, IMD3, T-BAM}, IL2 (interleukin 2) [NCBI Gene 3558] {aka IL-2, TCGF, lymphokine}, AKT1 (AKT serine/threonine kinase 1) [NCBI Gene 207] {aka AKT, PKB, PKB-ALPHA, PRKBA, RAC, RAC-ALPHA}, CD69 (CD69 molecule) [NCBI Gene 969] {aka AIM, BL-AC/P26, CLEC2C, EA1, GP32/28, MLR-3}
- **Diseases:** diabetic (MESH:D003920), inflammatory (MESH:D007249), cytotoxicity (MESH:D064420), neuronal toxicity (MESH:D009410)
- **Cell lines:** Jurkat T — Homo sapiens (Human), Childhood T acute lymphoblastic leukemia, Cancer cell line (CVCL_0065)

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC11925290/full.md

## Figures

7 figures with captions in the complete paper: https://tomesphere.com/paper/PMC11925290/full.md

## References

36 references — full list in the complete paper: https://tomesphere.com/paper/PMC11925290/full.md

---
Source: https://tomesphere.com/paper/PMC11925290